The US Food and Drug Administration has announced a public hearing on psychedelic therapies, scheduled for 14 September 2026, in a move that could signal a shift in the regulatory landscape for mental health treatments. The hearing will gather evidence on the safety and efficacy of psychedelic compounds, including psilocybin, MDMA, and LSD, as potential therapies for conditions such as depression, PTSD, and anxiety.
Investment bank Jefferies has noted that the FDA appears increasingly willing to consider COMP360, a proprietary synthetic psilocybin formulation developed by UK-based biotech company Compass Pathways. In a research note, Jefferies analysts said the hearing could provide a clearer regulatory pathway for COMP360, which is currently in late-stage clinical trials for treatment-resistant depression. The analysts described the FDA's move as 'encouraging' for the sector.
Shares in Compass Pathways, which is listed on the Nasdaq but headquartered in London, have risen in recent weeks on the back of the regulatory news. The FTSE 100 has remained relatively flat, but the broader biotech sector has seen renewed interest, with investors betting on a new class of mental health treatments. Analysts caution, however, that regulatory approval is not guaranteed and that the hearing is only the first step in a lengthy process.
For UK investors and pension holders with exposure to global biotech funds, the hearing represents a potential catalyst. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has not yet signalled its own position on psychedelics, but US regulatory moves often influence British policy. If the FDA approves COMP360, it could open the door for NHS adoption, though cost and clinical evidence remain key hurdles.
Industry commentators note that the psychedelic therapy market could be worth billions if regulators give the green light. However, risks remain high, including safety concerns, stigma, and the complexity of delivering psychedelic-assisted therapy in a clinical setting. The September hearing will be closely watched by investors, clinicians, and patient groups on both sides of the Atlantic.